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ABSTRACT 
The combination of folinate salts to 5-fluoruracil (5-FU)-based schedules is an 
established clinical routine in the landscape of the colorectal cancer treatment. The aim 
of this study was to investigate the pharmacological differences between the sequential 
administration of folinate salts (1 h before, as in clinical routine) followed by 5-FU and 
the simultaneous administration of both drugs. Proliferation and apoptotic assays were 
performed on human colon cancer cells exposed to 5-FU, calcium (CaLV) or disodium 
(NaLV) levofolinate or their simultaneous and sequential combination for 24 and 72h. 
TYMS and SLC19A1 gene expression was performed with real time PCR. In vivo 
experiments were performed in xenografted nude mice, treated with 5-FU escalating 
doses and CaLV or NaLV alone or in simultaneous and sequential combination. The 
simultaneous combination of folinate salts and 5-FU was synergistic (NaLV) or additive 
(CaLV) in a 24h treatment in both cell lines. In contrast, the sequential combination of 
both folinate salts and 5-FU was antagonistic at 24 and 72h. The simultaneous 
combination of 5-FU and NaLV or CaLV inhibited TYMS gene expression at 24h, 
whereas the sequential combination reduced SLC19A1 gene expression. In vivo 
experiments confirmed the enhanced antitumor activity of the 5-FU+NaLV 
simultaneous combination with a good toxicity profile, whereas the sequential 
combination with CaLV failed to potentiate 5-FU activity. In conclusion, only the 
simultaneous, but not the consecutive, in vitro and in vivo combination of 5-FU and 
both folinate salt formulations potentiated the antiproliferative effects of the drugs.  
 
Key words: colon cancer; 5-fluorouracil; calcium levofolinate; disodium levofolinate; 
synergism; TYMS; SLC19A1 
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INTRODUCTION 
5-Fluorouracil (5-FU) and other fluoropyrimidines (e.g. capecitabine, UFT, S-1, 
TAS-102), still represent essential drugs in combination regimens for the adjuvant or 
first/second line treatment of solid tumors such as colorectal neoplasms 1-3. Their main 
mechanism of action involves the inhibition of thymidylate synthase (TS) by the active 
metabolite 5-fluoro-deoxyuridine-monophosphate (5-FdUMP) in the presence of folate 
(5,10-methylenetetrahydrofolate), a required cofactor for the reaction 1. The formation 
of the ternary complex 5-FdUMP/TS/folate with covalent bonds leads to the 
stabilization of the complex itself, with prolonged inhibition of TS catalytic activity 1,4. On 
the basis of these observations, the modulation of inhibitory effects of the 
fluoropyrimidines by folinate salts has been developed in preclinical and clinical 
settings, showing a preclinical enhancement 5-7 and a better clinical response to 5-
FU/levofolinate combined treatment compared to the fluoropyrimidine alone 8.  
Unfortunately, the simultaneous use of folinic acid salified with calcium, and 
mixed with the 5-FU, determined the precipitation of the formed calcium carbonate 9 
and subsequent catheter obstruction 10-12. Indeed, soon it became evident in patients 
that the simultaneous 5-FU and calcium levofolinate (CaLV) mix and infusion in a 
single catheter was impossible, and 5-FU and CaLV were infused with the aid of two 
separate pumps 10. Thereafter, a sequential administration CaLV followed by 5-FU 
(administered first as bolus injection, then as continuous or chronomodulated infusions) 
was adopted in the clinical routine and now represents the standard therapeutic 
scheme to which new drugs have been added over the years, such as irinotecan, 
oxaliplatin, cetuximab and bevacizumab 13.  
At the beginning of 2000s, the therapeutic armamentarium included both the 
CaLV and the newer formulation disodium levofolinate (NaLV) 14,15. The latter showed 
comparable efficacy to the CaLV, with an objective response rate of 37.2 % in patients 
with advanced rectal cancer 14. However, it was noted that in 51 evaluable patients, the 
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use of NaLV seemed favorably associated with a best time to progression 14. More 
recently, a phase II randomized study of combined infusional NaLV and 5-FU vs. the 
CaLV followed by 5-FU, both in combination with irinotecan or oxaliplatin in patients 
with metastatic colorectal cancer, showed the same overall response rate in both the 
study arms with a comparable safety 16. The favorable toxicity profile of the 
simultaneous clinical combination of 5-FU and NaLV was also recently confirmed in a 
24h-infusion schedule 17. The NaLV formulation can be easily administered 
simultaneously to 5-FU admixed in one ambulatory pump because it does not 
precipitate in the solution. This characteristic may have several clinical and nursing 
advantages, such as a shortening of the time necessary for the administration of drugs 
(with a consequent decrease in human resources) and a reduced discomfort for the 
patient 18, if compared to the sequential administration of CaLV followed by 5-FU.  
The aims of the present study were i) to determine the effects of simultaneous 
administration of 5-FU and NaLV or CaLV on colon cancer cells compared to the 
sequential combination of the two drugs (CaLV or NaLV 1 h treatment before 5-FU 
administration), investigating both the antiproliferative and pro-apoptotic effects, and 
the changes in Thymidylate Synthetase (TYMS) and Solute Carrier Family 19 Member 
1 (SLC19A1) gene expression; ii) to evaluate the in vivo activity of 
simultaneous/consecutive administration of 5-FU and  CaLV or NaLV on human colon 
cancer xenografts.  
 
MATERIALS AND METHODS 
Drugs, Cell Lines and Reagents 
5-FU, NaLV and CaLV were generously provided by MEDAC (Wedel, 
Germany). The drugs were dissolved in sterile water at a concentration of 1 mM before 
their in vitro and in vivo use. 
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The human colon cancer cell lines HT-29 (B-raf mutated) and Caco-2 (wild 
type) were used between passage 2 and 5 from the original vial obtained by the 
American Type Culture Collection (Rockville, USA). Cells were cultured in sterile flasks 
of 75 cm2 at 37 °C and 5% CO2. Cells were maintained in RPMI 1640 medium (Sigma-
Aldrich, Milan, Italy), supplemented with penicillin 50 IU/ml, streptomycin 50 μl/ml, and 
with 10% fetal bovine serum (FBS) for the entire duration of in vitro experiments. 
Each cell line was characterized for polymorphisms in the promoter region of 
the TS gene (thymidylate synthase enhancer region, TSER) by PCR amplifying a 
fragment containing 2 (TSER*2, 2R) or three repeats (TSER*3, 3R) of 28 bp in a 
thermocycler ABI PRISM 9700 (Life Technologies, Thermo Fisher Scientific 
Corporation, Carlsbad, USA) using the following primers 19:  
forward 5'- GTGGCTCCTGCGTTTCCCCC -3'; 
reverse 5'- TCCGAGCCGGCCACAGGCAT -3'.  
The PCR analysis was performed in a total volume of 25 μl containing 200 ng 
DNA, 2 μl of 10 mM each primer, 0.5 μl of 10 mM deoxynucleotide Mix (Sigma-Aldrich), 
0.15 U of 5U/μl GoTaq® DNA Polymerase (Promega, Milan, Italy), 2.5 μl of 5x Buffer 
with MgCl2 (Promega, Milan, Italy) and water DNase/RNase free. Cycling conditions 
were 1 cycle at 94°C for 5 min with hot start; 30 cycles of 40 sec at 94°C, 1 min at 62°C 
and 40 sec at 72°C; and 1 cycle elongation for 5 min at 72°C 20. PCR products were 
maintained at 4 °C until electrophoresis on 3% agarose gel labeled with ethidium 
bromide.  
 
Antiproliferative Effects of Drugs 
Cells were seeded into sterile 24-well plates (3x106 cells/well). After 24h cells 
were treated with 5-FU, CaLV and NaLV (from 0.01 to 100 μM) for 24, 48, and 72h, 
whereas a group of control cells were exposed to vehicle alone (saline). After 
exposure, the cells were detached and viable cells were counted by the ADAM-MC cell 
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counter (Digital Bio, NanoEnTek Inc., Seoul, South Korea) as previously described 21. 
Results were expressed as a percentage of the vehicle-treated control. The 
concentration level of the drugs which induced 50% of cell proliferation inhibition (IC50) 
was calculated using the software GraphPad Prism v. 5.0 (GraphPad Software Inc., 
San Diego, CA, USA) with a non-linear regression method. Each experiment was 
conducted in triplicate, considering 9 wells for each drug concentration tested. 
 
In Vitro Combination Studies 
To evaluate the type of interaction (i.e. synergistic, additive, and antagonistic) 
between the drugs, 5-FU combined with NaLV or CaLV was explored with two different 
treatment schedules for 24h and 72h at a fixed molar concentration ratio of 1:1 in HT-
29 and Caco-2 cells, as follows: (A) a simultaneous exposure with 5-FU (0.1-100 µM) 
plus NaLV or CaLV (0.1-100 µM) for 24h or 72h; (B) a sequential exposure with NaLV 
or CaLV (0.1-100 µM) given alone for 1 h, then 5-FU (0.1-100 µM) plus NaLV or CaLV 
(0.1-100 µM) were added for 24h or 72h. After drug exposure, the media of cell 
cultures were discarded and cells counted. Each experiment was conducted in 
triplicate, considering 9 wells for each drug concentration tested. 
The effect of combination treatments was then assessed by the software 
CalcuSyn v. 2.0 (Biosoft, Cambridge, UK) using the method of Chou 22. Briefly, the 
synergistic, additive or the antagonistic effect for 5-FU plus NaLV or CaLV was 
calculated on the basis of the multiple drug-effect equation, and quantified by the 
combination index (CI), where CI<1, CI=1 and CI>1 indicate synergism, additive effect 
and antagonism, respectively. Based on the classic isobologram, the CI value was 
calculated according to the following formula: 
CI = [(D)1/(Dx)1] + [(D)2/(Dx)2] 
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where (Dx)1 and (Dx)2 are the IC50 values of the two drugs used alone, whereas (D)1 
and (D)2 are the concentrations of the two drugs in combination to inhibit 50% cell 
growth. 
 
Evaluation of Apoptosis 
To quantify the apoptosis induced by the aforementioned pharmacological 
treatments, HT-29 and Caco-2 cell lines were treated for 24h alone and in combination 
5-FU 2 µM, NaLV 2 µM and CaLV 2 µM (at the fixed molar concentration ratio of 1:1). 
After incubation with drugs, cells were collected and analyzed using the Cell Death 
Detection ELISA Plus Kit (Roche, Basel, Switzerland) as per manufacturer’s 
instructions. The optical density was measured using a Multiskan Spectrum microplate 
reader (Thermo Labsystems, Milan, Italy) set to a wavelength of 405 nm (with a 
wavelength of 490 nm correction). All experiments were repeated three times with at 
least three replicates per sample. 
 
Evaluation of TYMS and SLC19A1 Gene Expression 
The assessment of TYMS and SLC19A1 gene expression in tumor cells - 
exposed for 24h alone and in combination with 5-FU 2 µM, NaLV 2 µM and CaLV 2 µM 
(at the fixed molar concentration ratio of 1:1) - was conducted measuring mRNA 
concentrations by using the polymerase chain reaction after reverse transcription (RT-
PCR). The mRNA concentration (μg/μL) was determined by measuring the absorbance 
at a wavelength of 260 nm. The reverse transcription reaction was carried out in a 
volume of 20 μl of a mixture containing the extracted RNA (2 μg), dNTP (0.8 mM), oligo 
(DT6) primers (50 μg/μL), MLV-RT (10 U/μL), 5x RT buffer, DTT (5 mM) and RNase 
inhibitor (2.5 U/μL). Reaction mixture was incubated at 37 °C for 1 hour in a ABI PRISM  
9700 thermocycler (Life Technologies), and the cDNA was stored at -20 °C.  
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The quantification of gene expression (RT-PCR) of TYMS (Assay ID 
Hs00426586_m1), SLC19A1 (Assay ID Hs00953344_m1) and the endogenous control 
gene GAPDH (Assay ID 4326317E) was performed by using TaqMan primers and 
probes (Life Technologies). Amplification reactions were performed in triplicate in 96-
well plates in a total volume of 25 μl, containing cDNA equivalent to 20 ng of total RNA 
(5 μL), primers at optimal concentrations, 100 nM probe, and 12.5 μl of TaqMan 
Universal PCR master mix (Life Technologies). PCR was performed according the 
following steps: 50 °C/2 min, 95 °C/10 min, then 40 cycles at 95 °C/15 sec and 60 °C/1 
min. Data were analyzed by PCR using the ABI PRISM program 7900HT Sequence 
Detector Software (Life Technologies). All experiments were repeated three times with 
at least three replicates per sample. 
The PCR thermal cycling conditions and the optimization of primer 
concentrations were as per the manufacturer’s instructions. Amplifications were 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the 
quantification of gene expression was performed using the ΔΔCt calculation, where Ct 
is the threshold cycle. The amount of target, normalized to the endogenous control and 
relative to the calibrator (i.e., vehicle-treated control cells), was calculated using the 
formula 2−ΔΔCt. 
 
Animals 
Athymic Nude-Foxn1nu male mice, weighing 25 g, were supplied by Envigo 
(Milan, Italy) and were allowed unrestricted access to sterile food and water. Housing 
and all procedures involving animals were performed according to the protocol firstly 
approved by the Academic Organization Responsible for Animal Welfare (OPBA, 
Organismo Preposto per il Benessere Animale) of the University of Pisa, in accordance 
with the Italian law D.lgs. 26/2014, and by the Italian Ministry of Health (authorization 
Copyright © 2017 Cognizant Communication Corporation 
EU-1006 Oncology Research E-pub 
 
number 557/2015-PR). Each experiment employed the minimum number of mice 
needed to obtain statistically meaningful results. 
 
Subcutaneous HT-29 Xenografts  
Animals were anesthetized with a combination (1:1) of tiletamine and 
zolazepam (Zoletil®) 50 mg/kg i.p. before inoculation procedure. HT-29 cell viability 
was assessed by trypan blue dye exclusion, and, on day 0, 1.3×106±5% cells per 
mouse were inoculated subcutaneously between the scapulae in 0.2 ml of culture 
medium without FBS, using an insulin syringe with a 0.5×16 mm needle. Animal 
weights were monitored and upon the appearance of a subcutaneous mass, tumor 
dimensions were measured using calipers (by two trained and expert technicians, 
independently). Caliper measurements were carried out every two days to determine 
tumor growth and tumor volume. Tumor volume (mm3) was measured as follows: [(w1 x 
w1 x w2) x (π/6)], where w1 and w2 were the smallest and the largest tumor diameter 
(mm), respectively. The mice were randomized into groups of six animals (n=6) and 
were administered with the experimental schedules when the mean of tumor volumes 
was around 100 mm3. Data analysis was conducted by an investigator blinded to which 
group of animals represented treatments or controls. 
Three different experiments were performed using escalating doses of 5-FU. In 
the first experiment, animals were randomized in four groups: group 1 (control group) 
was administered with vehicle alone (saline); group 2 received 5-FU 50 mg/kg i.p. once 
a week; group 3 received the CaLV 50 mg/kg i.p. once a week (slow infusion), followed 
1h later by 5-FU 50 mg/kg i.p.; group 4 was treated with 5-FU 50 mg/kg i.p and NaLV 
50 mg/kg, simultaneously in the same syringe. In the second experiment, animals were 
randomized in five groups: group 1 (control group) was administered with vehicle alone 
(saline); group 2 received 5-FU 100 mg/kg i.p. once a week; the group 3 received the 
CaLV 50 mg/kg i.p. once a week (slow infusion), followed 1h later by 5-FU 100 mg/kg 
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i.p.; group 4 and group 5 were treated with the simultaneous combination of 5-FU 100 
mg/kg i.p plus NaLV 50 mg/kg (in the same injection) or CaLV 50 mg/kg i.p. (in 
separate injections), respectively. In the last experiment, animals were randomized in 
five groups: group 1 (control group) was administered with vehicle alone (saline); group 
2 received 5-FU 150 mg/kg i.p. once a week; group 3 received the CaLV 50 mg/kg i.p. 
once a week (slow infusion), followed 1h later by 5-FU 150 mg/kg i.p.; group 4 and 
group 5 were treated with the simultaneous combination of 5-FU 150 mg/kg i.p plus 
NaLV 50 mg/kg (in the same injection) or CaLV 50 mg/kg i.p. (in separate injections), 
respectively. At the end of the study, animals were sacrificed with an overdose of 
anesthetic.  
 
Statistical Analysis 
Analysis of variance (ANOVA), followed by Student-Newman-Keuls test was 
used to compare data among different groups in in vitro and in vivo experiments. P 
values less than 0.05 were considered significant. Statistical analyses were performed 
using the GraphPad Prism software package version 5.0. 
 
RESULTS 
5-FU Inhibited Tumor Cell Proliferation in a Time- and Concentration-Dependent 
Manner 
The analysis of DNA extracted from both HT-29 and Caco-2 cells revealed a TS 
promoter genotype of TSER 2/2.  
5-FU has shown a significant time- and concentration-dependent inhibitory 
activity on cell proliferation. Indeed, the maximum effect of 5-FU was obtained in HT-29 
cells at 72h (IC50s 0.45±0.01 µM), whereas the Caco-2 cell line was slightly less 
sensitive to 5-FU concentrations at all the time points (e.g., 1.32±0.50 µM at 72h). 
Table 1 reports all the calculated IC50s at 24, 48 and 72h for the 5-FU drug in both the 
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colon cancer cell lines. The in vitro NaLV and CaLV IC50s were experimentally 
achieved in order to calculate the synergistic, additive or antagonistic interaction 
between drugs, but resulted extremely high (>50 µM) in both cancer cell lines at all the 
time points (data not shown). 
 
In Vitro Studies of Simultaneous or Consecutive Combination of 5-FU and NaLV or 
CaLV After 24 or 72 h Exposure 
In order to mimic the clinical settings of the simultaneous infusion of NaLV plus 
5-FU and the consecutive administration of CaLV 1h before of 5-FU injection, both the 
in vitro schedules were studied at 24h and 72h.  
 
Synergistic and Additive Effects of Simultaneous Combination of 5-FU and NaLV or 
CaLV After 24 h Exposure 
Simultaneous exposure of HT-29 and CaCo-2 cells to different concentrations 
of 5-FU and NaLV for 24h showed a strong synergism for 50% fraction of affected cells 
(CI<1, table 2). Interestingly, also the simultaneous treatments of 5-FU and CaLV for 
24h in both CaCo-2 and HT-29 cells had additive effects for 50% fraction of affected 
cells (CI equal or around 1, table 2).  
 
Antagonistic Effects of the Sequential Treatment of NaLV or CaLV (1 h) Followed by 5-
FU After 24 h Exposure 
Sequential exposure of HT-29 cells to different concentrations of NaLV (1 h 
before) and then 5-FU for 24 h showed an unexpected antagonism for all the 
percentages of fraction affected of cells (CI>1, table 2). Furthermore, also the 
sequential treatments of CaLV (1 hour) followed by 5-FU for 24h in HT-29 cells were 
strongly antagonist for 50% fraction of affected cells (CI>1, table 2). 
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Different Effects of the Simultaneous Treatments of 5-FU and NaLV or CaLV After 72 h 
Exposure in the Two Cell Lines 
Simultaneous exposure of Caco-2 and HT-29 cells to different concentrations of 
5-FU and NaLV for 72h showed a synergistic effect for 50% fraction of affected cells 
(CI<1, table 2). In contrast, the simultaneous treatments of 5-FU and CaLV for 72h in 
Caco-2 cells resulted frankly antagonistic (CI>1, table 2), whereas a moderate 
synergistic effect was maintained in the more sensitive HT-29 cell line (table 2).  
 
Antagonistic Effects of the Sequential Treatment of NaLV or CaLV (1 h) Followed by 5-
FU After 72 h Exposure 
Sequential exposure of Caco-2 and HT-29 cells to different concentrations of 
NaLV (1 h before) and then 5-FU for 72h showed a marked antagonism for 50% 
fraction of affected cells (CI>1, table 2). Moreover, also the sequential treatments of 
CaLV (1 hour) followed by 5-FU for 72h in both cell lines were highly antagonist for half 
of affected cells (CI>1, table 2). 
 
Induction of Apoptosis by the Simultaneous Combination of 5-FU and NaLV or CaLV in 
Colon Cancer Cells 
The extent of DNA fragmentation was significantly higher after 24h in HT-29 
cells treated with the simultaneous combination of 5-FU and NaLV (figure 1A; *P<0.05 
vs. vehicle-treated cells) and, although in a minor extent, with the simultaneous 
combination of 5-FU and CaLV (figure 1B; *P<0.05 vs. vehicle-treated cells). Both 
NaLV and CaLV alone did not modulate the apoptotic process after 24h. Interestingly, 
both the sequential combinations (CaLV or NaLV followed by 5-FU) slightly enhanced 
the presence of chromatin fragments but they did not reach a statistical significance if 
compared to Caco-2 and HT-29 vehicle-treated cells (figure 1A and B). 
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5-FU and NaLV or CaLV Simultaneous Combination Inhibited TYMS Gene Expression 
in Colon Cancer Cells 
To study the effect of the treatment with 5-FU, NaLV and CaLV alone and in 
simultaneous or sequential combination on the variation of TYMS expression, the gene 
expression of the 5-FU target was quantified in HT-29 colon cancer cell line after 24h. 
Figure 2 shows the significant inhibition (*P<0.05 vs. vehicle-treated cells) of the TYMS 
expression of cancer cells by 5-FU treatment and, above all, by the simultaneous 
combination of 5-FU and NaLV or CaLV (although in a lesser extent). Both NaLV and 
CaLV alone seem not to change significantly the TYMS gene expression. The 
sequential combination of NaLV or CaLV (1 h) and then 5-FU did not significantly 
change the TYMS expression after 24h if compared to vehicle-treated cancer cells 
(figure 2). 
 
NaLV or CaLV and 5-FU Sequential Combination Inhibited SLC19A1 Gene Expression 
in HT-29 Colon Cancer Cells 
To investigate the effect of the treatment with 5-FU, NaLV and CaLV alone and 
in simultaneous or sequential combination on the variation of SLC19A1 expression was 
quantified in HT-29 colon cancer cell line exposed for 24 hours. Figure 3 shows the 
significant inhibition (*P<0.05 vs. vehicle-treated cells) of the SCL19A1 expression of 
cancer cells by the sequential NaLV (1h before) plus 5-FU treatment and, above all, by 
the sequential CaLV (1h before) plus 5-FU treatment. On the contrary, the 
simultaneous combination of NaLV or CaLV plus 5-FU did not significantly change the 
SCL19A1 expression after 24h if compared to vehicle-treated cancer cells (figure 3), 
as well as the drugs administered alone. 
 
HT-29 Colon Cancer Tumor Xenografts In Vivo Studies 
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To evaluate the in vivo effect of the treatments on subcutaneous HT-29 tumors, 
three different experiments were performed using escalating doses of 5-FU (50, 100 
and 150 mg/kg) combined with NaLV (50 mg/kg) or CaLV (50 mg/kg) simultaneously, 
and in the case of CaLV also in a sequential manner. 
 
Experiment With 5-FU Dose of 50 mg/kg 
HT-29 cells injected s.c. in CD nu/nu mice grew quite rapidly and tumor masses 
became detectable 6-10 days after xenotransplantation. Tumors in control animals 
showed a progressive enlargement in their dimensions, and a mean volume of 3,774 
mm3 was reached at the end of the experimental period at day 25 (Figure 4A). Both 5-
FU alone and the simultaneous combination of 5-FU+NaLV were able to significantly 
inhibit tumour growth, and their therapeutic effect was significant starting on the 4th day 
after the beginning of the therapeutic schedule as compared to controls (Figure 4A). 
However, the simultaneous combination maintained a significant inhibitory effect during 
all the experimental period. Indeed, the tumor growth curve of NaLV+5-FU showed a 
divergent profile from that of 5-FU alone starting at days 18. On the contrary, in the 
group of animals receiving the combined, but sequential, treatment with CaLV followed 
1 hour later by 5-FU, the reduction in tumor growth was not present, and the profile of 
the curve was superimposable to the one of controls (Figure 4A). Animals of both 
controls and CaLV+5-FU combination groups were sacrificed at day 25 for the high 
tumor volumes. Interestingly, all the drug schedules showed a constant tumor increase 
in all the treated groups, but with a significant delay in the case of the 5-FU+NaLV 
combination treatment. The toxicity profile was favourable at this dose level and 
acceptable for all the treatment groups, with a small loss of weight throughout the 
course of the experiment (Figure 4B). 
 
Experiment With 5-FU Dose of 100 mg/kg 
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Injected HT-29 cells grew rapidly, and tumor masses became detectable 6 days 
after xenotransplantation. A mean volume of 3,973 mm3 was reached at day 34 when 
the animals of the control group were sacrificed (Figure 5A). Both 5-FU and the 
simultaneous association of 5-FU+NaLV were able to significantly inhibit the tumor 
growth, and their efficacy became significant starting on the seventh and the fifth day, 
respectively after the beginning of treatments as compared to controls (Figure 5A). On 
average, the 5-FU+NaLV schedule was more effective, especially from day 23 until the 
end of the experiment. It is noteworthy that in the groups of animals receiving the 
simultaneous and sequential combination of 5-FU+CaLV the initial response was 
superimposable to the 5-FU alone group and significantly different from controls until 
day 14 (Figure 5A). However, at that day the experimental period finished due to their 
toxicity profiles as described below.  
Figure 5B shows the toxicity profiles of the four different treatment schedules. 
Both 5-FU and 5FU+NaLV treatments were favorable and acceptable with a minor loss 
of weight throughout the course of the treatment (Figure 5B), whereas both the 
simultaneous 5-FU+CaLV combination and the sequential CaLV and 5-FU association 
caused a severe toxicity and a loss of weight that necessitated veterinary assistance at 
day 12 with an immediate fluid therapy (0.9% saline) and then at day 14, due to the 
nadir of body weight loss, the ethical sacrifice of all the animals, as suggested by 
guidelines (arrow, Figure 5B). It is noteworthy that the animals belonging to the 
simultaneous 5FU+NaLV combination group had a similar body weight profile to those 
treated with 5-FU alone (Figure 5B). 
 
Experiment With 5-FU Dose of 150 mg/kg 
Tumors in control animals showed a rapid enlargement in their dimensions; a 
mean volume of 392 mm3 was reached at day 8 when the experiment was closed 
(Figure 6A). Both the simultaneous 5-FU+NaLV and 5-FU+CaLV were able to 
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significantly inhibit the tumor, and their efficacy became significant starting on the third 
day, after the single injection of high dose of 5-FU as compared to controls (Figure 
6A). On average, the simultaneous combination schedules were more effective if 
compared to 5-FU alone and to the sequential administration of CaLV followed by 5-
FU. Interestingly after day 6 the initial response of this schedule was lost and the tumor 
volumes of this group of mice started to grow similarly to the controls (Figure 6A). 
However, at that day the experimental period finished due to their toxicity profiles as 
described below.  
Figure 6B shows the toxicity profiles of the four different treatment schedules. 
At this high 5-FU dose, the lack of weight is immediate for all the treated groups. Since 
the primary objective of this experiment was to establish the rapid antitumor effects of 
the schedules, the mice were sacrificed before the development of severe toxicity and 
weigh loss expected by the administered 5-FU dose. 
 
DISCUSSION 
The association of folinate salts to 5-FU-based schedules is an established 
clinical routine in the landscape of the colorectal cancer treatment because it has been 
experimentally proven to be active in past observations both in preclinical 5-7 and 
clinical settings 8,23.  
In vitro experiments of the early nineties 7,24 suggested that prolonged 
simultaneous exposure to both 5-FU and folinic acid would increase cytotoxicity in 
human cancer cell lines in a schedule-dependent manner. Moreover, it was also 
demonstrated that simultaneous prolonged exposure to folinic acid during 5-FU 
administration might be optimal for the intracellular formation of the stable ternary 
complex with thymidilate synthase, 5-FU metabolites and folinic acid derivatives  25. 
Ardalan and colleagues firstly translated these preclinical data in the clinical setting, 
treating patients with the simultaneous administration of 5-FU and CaLV 10. However, 
Copyright © 2017 Cognizant Communication Corporation 
EU-1006 Oncology Research E-pub 
 
the crystallization of calcium salts with the consequent blockage of the catheters led 
the authors to use two separate pumps 10 in order to finish the clinical study. Based on 
these evidences, a 1- or 2-hour infusion of CaLV preceding 5-FU administration was 
introduced into the clinic for its better practicability 26. This schedule become widely 
used, especially in European countries. However, as well pointed out by Luftner and 
colleagues in an editorial appeared in 2003, “this mode of application represented a 
compromise between the need for one i.v. device only and the pharmacological 
rationale of parallel toxification of 5-FU by folinic acid. However, keeping in mind the 
half lives of folinic acid with approximately 7 hours and 5-FU with a few minutes, this 
compromise a priori renounces optimal toxification of 5-FU, especially towards the end 
of the 24-h infusion” 27. 
The aim of the present study was to better investigate if there were relevant 
pharmacological differences between the sequential administration of folate salts (1 h 
before) followed by 5-FU (a schedule adopted in the clinical routine mainly for practical 
reasons rather than on the basis of experimental results) and the simultaneous 
administration of both drugs in vitro and in vivo settings. Indeed, our in vitro data seem 
to suggest some important differences on the activity of the combination of 5-FU and 
NaLV or CaLV in both colon cancer cell lines with the same TSER genetic profile but 
with different mutation status (i.e. HT-29 b-raf mutated, Caco-2 wild type). As expected 
by the previous published scientific literature, the simultaneous combination of both 
folinate salts with 5-FU enhanced the antiproliferative activity of the chemotherapeutic 
drug; in particular, the association of NaLV and 5-FU was synergistic at 24 and 72h, 
whereas the combination with CaLV was simply additive in the 24 h schedule. Instead, 
and surprisingly, the sequential combination of NaLV or CaLV (1 h before) and then 5-
FU resulted not additive but even antagonistic in a 24 and 72h treatment. Moreover, 
the simultaneous combination (but not the sequential one) of 5-FU and NaLV or CaLV 
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(although in a lesser extent) significantly increased also the percentages of apoptotic 
cells after 24 h treatments. 
A possible explanation of this counterintuitive antagonistic effect may come 
from the gene expression analysis of treated cancer cells. Indeed, the sequential 
combination (but not the simultaneous one) of 5-FU and CaLV or NaLV (although in a 
much lesser extent) significantly inhibited the folate transporter SLC19A1 (solute carrier 
family 19, member 1) gene expression after 24 h exposure. SLC19A1/RFC-1 is 
ubiquitously expressed and is the major folate transporter in mammalian cells and 
tissues 28,29. The SLC19A1/RFC-1 gene encodes the reduced folate carrier which 
functions optimally at physiological pH, transferring reduced folates, including 
leucovorin, into the cells 30. Interestingly, Odin and colleagues 31 significantly 
associated SLC19A1/RFC-1 expression with the disease-free survival of colorectal 
cancer patients treated with a 5-FU-based therapy using leucovorin. The authors 
suggested that the poor response to 5-FU plus leucovorin therapy in some patients 
was linked to low expression of this gene 31. The low expression of the folate transport 
gene SLC19A1/RFC-1 in tumor cells after the sequential administration of the two 
drugs, would result in lower levels of intracellular folates, and a reduced stabilization of 
the ternary complex comprising the active cofactor 5,10-methylenetetrahydrofolate, the 
thymidylate synthase and fluorinated dUMP, and may correlate with a decreased effect 
of the combination, measured by antiproliferative and proapoptotic activity. On the 
contrary, the simultaneous combination of folinate salts and 5-FU did not alter the 
transporter expression, making available a higher amount of stable ternary complexes 
with a strong synergistic antiproliferative effect. This result is unlikely related to 5-FU, 
considering that this drug enter the cells by transport mechanisms unrelated to 
SLC19A1/RFC-1 32.  
However, other folate pathway genes than the analyzed SLC19A1/RFC-1 are 
likely to be of importance. For instance, the expression of the gene TYMS which 
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encodes the 5-FU target thymidylate synthase, is known to affect response to 
treatment 33. In our experiments, the simultaneous combination (but not the sequential 
one) of 5-FU and NaLV or CaLV (although in a lesser extent) significantly inhibited the 
TYMS gene expression after 24 h exposure. Of note, TYMS is known to play a central 
role in 5-FU response to therapy because the higher expression of TYMS has been 
previously reported to be associated with the resistance to 5-FU 34,35. Among resistance 
mechanisms reported so far, tumors with elevated TYMS have been shown to have 
highly proliferative and metastatic characteristics 36; moreover 5-FU sensitivity and 
patients’ survival have been inversely related to the level of TYMS protein and 
enzymatic activity in cancer cells, and 5-FU-resistant tumors commonly express high 
levels of TYMS protein 37. Thus, it is conceivable, at least in vitro, that the sequential 
administration, differently from the simultaneous one, of folinate salts and 5-FU may 
cause an antagonistic effect through the significant inhibition of the transport 
mechanism of folate, whereas, the simultaneous combination of the drugs may 
synergize its effects through the significant decrease of TYMS gene expression and an 
unchanged SLC19A1/RFC-1 expression. 
The in vivo experiments confirmed the enhanced antitumor activity of the 
simultaneous 5-FU plus NaLV combination at different 5-FU doses. These positive 
effects could be explained on the basis of our in vitro findings but also with the possible 
pharmacokinetic advantage of the simultaneous administration of the two drugs. 
Indeed, the NaLV maximum concentration, and thus the availability of LV in plasma 
and tissues, is contextual with the maximum concentration reached by 5-FU, 
enhancing the possibility of stabilization of the ternary complex that can be achieved by 
high levels of 5,10-methylenetetrahydrofolate 31. Moreover, this association obtained 
also a good toxicity profile in nude mice, similarly to the published clinical studies of 
Hartung et al. 14 and Kuhfahl et al. 15 on the simultaneous administration of NaLV and 
5-FU where no haematological toxicity grade III/IV was observed. On the contrary, the 
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sequential association of CaLV (1h before) 38 followed by 5-FU at the lowest and at the 
highest dose (50 and 150 mg/kg) did not exert a significant therapeutic effect, whereas 
at the 5-FU dose of 100 mg/kg, the combination showed an antitumor activity similar to 
5-FU alone but with the appearance of a severe toxicity that led to a precocious mice 
suppression. Unfortunately, combined administration of CaLV and 5-FU resulted in 
high grade toxicity. However, it cannot be excluded that this important toxicity may 
depend on the calcium salt formulation of the drug with the possible crystallization and 
precipitation of the formed calcium carbonate 9 during the simultaneous persistence in 
peritoneal cavity of the two drugs, although this event was not recorded at the autopsy 
of the mice.  
In conclusion, the simultaneous in vitro administration of folate salts with 5-FU 
leads to an enhanced antiproliferative effect. Unfortunately, this increased activity is 
lost in the sequential combination probably due to the inhibition of SLC19A1/RFC-1 
gene expression. The in vivo experiments confirmed the enhanced antitumor activity of 
the simultaneous combination of NaLV+5-FU with a good toxicity profile of this 
schedule. The present preclinical findings seem to suggest that folinate salts may be 
better administered with 5-FU simultaneously in a single pump (i.e. NaLV) or with the 
aid of two separate ones (i.e. CaLV), rather than sequentially, as currently applied in 
routine oncology practice. However, a confirmation of this preclinical data in a clinical 
setting could be achieved only through a properly designed phase III, randomized 
clinical trial. 
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Table 1. IC50 values of single drugs after 24, 48 and 72 hours of in vitro exposure 
drugs 
HT-29 CaCo-2 
IC50 ± SD [µM] IC50 ± SD [µM] 
5-FU 24 h 12.27±0.93 14.56±4.84 
5-FU 48 h 7.57±2.58 11.20±3.63 
5-FU 72 h 0.45±0.01 1.324±0.50 
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Table 2. Combination index (CI) values at 50% of affected cell fraction in human HT-29 
and Caco-2 colon cancer cells after 24 and 72h of simultaneous and consecutive 
combination treatment of 5-fluorouracile (5-FU) and sodium levofolinate (NaLV) or 
calcium levofolinate (CaLV) 
 
 
 
Simultaneous treatment 
5-FU + NaLV or CaLV 
Consecutive treatment  
NaLV or CaLV (1h) → 5-FU 
24h 72h 24h 72h 
Cell 
lines 
NaLV CaLV NaLV CaLV NaLV CaLV NaLV CaLV 
HT-29 0.427 1.340 0.811 0.906 4.136 32.462 9.297 2.584 
CaCo-
2 
0.793 1.063 0.962 27.974 4.923 7.778 12.622 23.076 
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FIGURE LEGENDS 
Figure 1. Apoptotic effects of sequential and simultaneous combinations of 5-FU (2 
µM), NaLV (2 µM) and CaLV (2 µM) on HT-29 (A) and Caco-2 (B) colon cancer cell 
lines treated for 24 hours. Columns and bars indicate mean values ± SD, respectively. 
*P<0.05 versus vehicle-treated controls. 
 
Figure 2. TYMS gene expression in HT-29 cells exposed for 24 hours to 5-FU alone 
and to the sequential and simultaneous combinations of 5-FU (2 µM), NaLV (2 µM) and 
CaLV (2 µM).  Columns and bars indicate mean values ± SD, respectively. *P<0 .05 
versus vehicle-treated controls. 
 
Figure 3. SCL19A1 gene expression in HT-29 cells exposed for 24 hours to sequential 
and simultaneous combinations of 5-FU (2 µM), NaLV (2 µM) and CaLV (2 µM). 
Columns and bars indicate mean values ± SD, respectively. *P<0 .05 versus vehicle-
treated controls. 
 
Figure 4. A) Chemotherapeutic effect of 5-FU 50 mg/kg i.p. alone and in simultaneous 
or sequential combination with NaLV or CaLV 50 mg/kg i.p. on HT-29 tumors 
xenotransplanted in CD nu/nu mice (n=6 for each group). *P<0.05 with respect to 
controls. Symbols and bars, mean ± SD. (B) Body weight of HT-29 tumor-bearing 
control mice and mice treated with 5-FU alone or in simultaneous or sequential 
combination with folinate salts. Symbols and bars, mean ± SD. 
 
Figure 5. A) Chemotherapeutic effect of 5-FU 100 mg/kg i.p. alone and in 
simultaneous or sequential combination with NaLV or CaLV 50 mg/kg i.p. on HT-29 
tumors xenotransplanted in CD nu/nu mice (n=6 for each group). *P<0.05 with respect 
to controls. Symbols and bars, mean ± SD. (B) Body weight of HT-29 tumor-bearing 
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control mice and mice treated with 5-FU alone or in simultaneous or sequential 
combination with folinate salts. Both the simultaneous 5-FU+CaLV combination and the 
sequential CaLV and 5-FU association caused a severe loss of mouse weight requiring 
fluid therapy (0.9% saline) at day 12, and then at day 14  the ethical sacrifice of all the 
animals (arrow). Symbols and bars, mean ± SD. 
 
Figure 6. A) Chemotherapeutic effect of the single injection of 5-FU 150 mg/kg i.p. 
dose  alone and in simultaneous or sequential combination with NaLV or CaLV 50 
mg/kg i.p. on HT-29 tumors xenotransplanted in CD nu/nu mice (n=6 for each group). 
*P<0.05 with respect to controls. Symbols and bars, mean ± SD. (B) Body weight of 
HT-29 tumor-bearing control mice and mice treated with 5-FU alone or in simultaneous 
or sequential combination with folinate salts. Symbols and bars, mean ± SD. 
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